Compare $MLYS vs $NVAX | Chartloom

Compare

$MLYS vs $NVAX

Mineralys Therapeutics Inc · Novavax Inc

MLYS

Mineralys Therapeutics Inc

NVAX

Novavax Inc

Compare $MLYS vs $NVAX

Comparing Mineralys Therapeutics Inc and Novavax Inc

MLYSMineralys Therapeutics Inc

NVAXNovavax Inc

MLYSMineralys Therapeutics Inc

Market cap

$2.06B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

30.20x

Rev growth (TTM)

—

YTD performance

-34.6%

52W performance

-37.7%

FCF yield

-16.5%

NVAXNovavax Inc

Market cap

$2.10B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

10.28x

Rev growth (TTM)

-61.6%

YTD performance

78.8%

52W performance

43.3%

FCF yield

-2.0%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

MLYS

NVAX

Detailed metrics comparison

MLYS

Mineralys Therapeutics Inc

NVAX

Novavax Inc

Market Cap

MLYS$2.06B

NVAX$2.10B

Enterprise Value

MLYS$2.02B

NVAX$2.20B

Price

MLYS$23.37

NVAX$12.75

P/E Ratio

MLYSN/A

NVAXN/A

P/S Ratio

MLYS0.00x

NVAX5.07x

EV/Sales

MLYS0.00x

NVAX5.32x

EV/EBITDA

MLYS0.00x

NVAX4.05x

P/B Ratio

MLYS3.79x

NVAX45.86x

P/FCF Ratio

MLYSN/A

NVAXN/A

EV/FCF

MLYS-5.96x

NVAX-51.40x

PEG Ratio

MLYSN/A

NVAXN/A

Forward P/E (NTM)

MLYSN/A

NVAXN/A

Forward P/S (NTM)

MLYS30.20x

NVAX10.28x

Revenue (TTM)

MLYS$0

NVAX$414M

Revenue Growth (YoY)

MLYSN/A

NVAX-61.6%

Forward Rev Growth

MLYS106.7%

NVAX-25.1%

Gross Margin (TTM)

MLYS0.0%

NVAX79.2%

Operating Margin (TTM)

MLYS0.0%

NVAX0.0%

EBITDA Margin (TTM)

MLYS0.0%

NVAX-24.0%

Net Margin (TTM)

MLYS0.0%

NVAX-59.9%

FCF Margin (TTM)

MLYSN/A

NVAX-10.4%

Net Income (TTM)

MLYS$-350M

NVAX$-248M

FCF (TTM)

MLYS$-339M

NVAX$-43M

EPS (TTM)

MLYS-$4.13

NVAX-$1.51

ROE (TTM)

MLYS-5797.0%

NVAX283.1%

ROA (TTM)

MLYS-5415.0%

NVAX-2275.0%

ROIC (TTM)

MLYS-5571.0%

NVAX40.0%

Cash

MLYS$138M

NVAX$191M

Debt

MLYS$98M

NVAX$297M

Net Cash/Debt

MLYS$41M

NVAX$-106M

Current Ratio (TTM)

MLYS34.46x

NVAX2.33x

Quick Ratio (TTM)

MLYS34.24x

NVAX2.23x

Debt/Equity (TTM)

MLYS0.18x

NVAX6.07x

Debt/Assets (TTM)

MLYS0.0%

NVAX0.0%

Interest Coverage (TTM)

MLYSN/A

NVAXN/A

Net Debt/EBITDA (TTM)

MLYS0.00x

NVAX0.00x

Beta

MLYS0.64

NVAX2.81

52W Performance

MLYS-37.7%

NVAX43.3%

YTD Performance

MLYS-34.6%

NVAX78.8%

% from 52W High

MLYS-51.0%

NVAX-4.7%

% from 52W Low

MLYS8.9%

NVAX105.6%

Asset Turnover (TTM)

MLYS0.00x

NVAX0.38x

FCF Yield (TTM)

MLYS-16.5%

NVAX-2.0%

Earnings Yield (TTM)

MLYS-17.0%

NVAX-11.8%

Dividend Yield (TTM)

MLYSN/A

NVAXN/A

Rule of 40

MLYS0.0

NVAX-72.0

EV/GP/RG

MLYSN/A

NVAXN/A

Ticker research

View MLYS research View NVAX research

Metric	MLYS Mineralys Therapeutics Inc	NVAX Novavax Inc
Market & Valuation
Market Cap	$2.06B	$2.10B
Enterprise Value	$2.02B	$2.20B
Price	$23.37	$12.75
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	5.07x
EV/Sales	0.00x	5.32x
EV/EBITDA	0.00x	4.05x
P/B Ratio	3.79x	45.86x
P/FCF Ratio	N/A	N/A
EV/FCF	-5.96x	-51.40x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	30.20x	10.28x
Revenue & Growth
Revenue (TTM)	$0	$414M
Revenue Growth (YoY)	N/A	-61.6%
Forward Rev Growth	106.7%	-25.1%
Profitability
Gross Margin (TTM)	0.0%	79.2%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-24.0%
Net Margin (TTM)	0.0%	-59.9%
FCF Margin (TTM)	N/A	-10.4%
Net Income (TTM)	$-350M	$-248M
FCF (TTM)	$-339M	$-43M
EPS (TTM)	-$4.13	-$1.51
ROE (TTM)	-5797.0%	283.1%
ROA (TTM)	-5415.0%	-2275.0%
ROIC (TTM)	-5571.0%	40.0%
Financial Health
Cash	$138M	$191M
Debt	$98M	$297M
Net Cash/Debt	$41M	$-106M
Current Ratio (TTM)	34.46x	2.33x
Quick Ratio (TTM)	34.24x	2.23x
Debt/Equity (TTM)	0.18x	6.07x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.64	2.81
52W Performance	-37.7%	43.3%
YTD Performance	-34.6%	78.8%
% from 52W High	-51.0%	-4.7%
% from 52W Low	8.9%	105.6%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.38x
FCF Yield (TTM)	-16.5%	-2.0%
Earnings Yield (TTM)	-17.0%	-11.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-72.0
EV/GP/RG	N/A	N/A
Ticker research	View MLYS research	View NVAX research

Valuation

P/S Ratio

MLYS

0.00x

NVAX

5.07x

EV/FCF

NVAX

-51.40x

MLYS

-5.96x

Growth & revenue

Revenue Growth TTM

NVAX

-61.6%

Forward Revenue Growth

MLYS

106.7%

NVAX

-25.1%

Profitability & performance

Gross Margin

NVAX

79.2%

MLYS

0.0%

ROE

NVAX

283.1%

MLYS

-5797.0%

FCF Yield %

NVAX

-2.0%

MLYS

-16.5%

52-Week Performance

NVAX

43.3%

MLYS

-37.7%

Detailed metrics comparison

MLYS

Mineralys Therapeutics Inc

NVAX

Novavax Inc

Market Cap

MLYS$2.06B

NVAX$2.10B

Enterprise Value

MLYS$2.02B

NVAX$2.20B

Price

MLYS$23.37

NVAX$12.75

P/E Ratio

MLYSN/A

NVAXN/A

P/S Ratio

MLYS0.00x

NVAX5.07x

EV/Sales

MLYS0.00x

NVAX5.32x

EV/EBITDA

MLYS0.00x

NVAX4.05x

P/B Ratio

MLYS3.79x

NVAX45.86x

P/FCF Ratio

MLYSN/A

NVAXN/A

EV/FCF

MLYS-5.96x

NVAX-51.40x

PEG Ratio

MLYSN/A

NVAXN/A

Forward P/E (NTM)

MLYSN/A

NVAXN/A

Forward P/S (NTM)

MLYS30.20x

NVAX10.28x

Revenue (TTM)

MLYS$0

NVAX$414M

Revenue Growth (YoY)

MLYSN/A

NVAX-61.6%

Forward Rev Growth

MLYS106.7%

NVAX-25.1%

Gross Margin (TTM)

MLYS0.0%

NVAX79.2%

Operating Margin (TTM)

MLYS0.0%

NVAX0.0%

EBITDA Margin (TTM)

MLYS0.0%

NVAX-24.0%

Net Margin (TTM)

MLYS0.0%

NVAX-59.9%

FCF Margin (TTM)

MLYSN/A

NVAX-10.4%

Net Income (TTM)

MLYS$-350M

NVAX$-248M

FCF (TTM)

MLYS$-339M

NVAX$-43M

EPS (TTM)

MLYS-$4.13

NVAX-$1.51

ROE (TTM)

MLYS-5797.0%

NVAX283.1%

ROA (TTM)

MLYS-5415.0%

NVAX-2275.0%

ROIC (TTM)

MLYS-5571.0%

NVAX40.0%

Cash

MLYS$138M

NVAX$191M

Debt

MLYS$98M

NVAX$297M

Net Cash/Debt

MLYS$41M

NVAX$-106M

Current Ratio (TTM)

MLYS34.46x

NVAX2.33x

Quick Ratio (TTM)

MLYS34.24x

NVAX2.23x

Debt/Equity (TTM)

MLYS0.18x

NVAX6.07x

Debt/Assets (TTM)

MLYS0.0%

NVAX0.0%

Interest Coverage (TTM)

MLYSN/A

NVAXN/A

Net Debt/EBITDA (TTM)

MLYS0.00x

NVAX0.00x

Beta

MLYS0.64

NVAX2.81

52W Performance

MLYS-37.7%

NVAX43.3%

YTD Performance

MLYS-34.6%

NVAX78.8%

% from 52W High

MLYS-51.0%

NVAX-4.7%

% from 52W Low

MLYS8.9%

NVAX105.6%

Asset Turnover (TTM)

MLYS0.00x

NVAX0.38x

FCF Yield (TTM)

MLYS-16.5%

NVAX-2.0%

Earnings Yield (TTM)

MLYS-17.0%

NVAX-11.8%

Dividend Yield (TTM)

MLYSN/A

NVAXN/A

Rule of 40

MLYS0.0

NVAX-72.0

EV/GP/RG

MLYSN/A

NVAXN/A

Ticker research

View MLYS research View NVAX research

Metric	MLYS Mineralys Therapeutics Inc	NVAX Novavax Inc
Market & Valuation
Market Cap	$2.06B	$2.10B
Enterprise Value	$2.02B	$2.20B
Price	$23.37	$12.75
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	5.07x
EV/Sales	0.00x	5.32x
EV/EBITDA	0.00x	4.05x
P/B Ratio	3.79x	45.86x
P/FCF Ratio	N/A	N/A
EV/FCF	-5.96x	-51.40x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	30.20x	10.28x
Revenue & Growth
Revenue (TTM)	$0	$414M
Revenue Growth (YoY)	N/A	-61.6%
Forward Rev Growth	106.7%	-25.1%
Profitability
Gross Margin (TTM)	0.0%	79.2%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-24.0%
Net Margin (TTM)	0.0%	-59.9%
FCF Margin (TTM)	N/A	-10.4%
Net Income (TTM)	$-350M	$-248M
FCF (TTM)	$-339M	$-43M
EPS (TTM)	-$4.13	-$1.51
ROE (TTM)	-5797.0%	283.1%
ROA (TTM)	-5415.0%	-2275.0%
ROIC (TTM)	-5571.0%	40.0%
Financial Health
Cash	$138M	$191M
Debt	$98M	$297M
Net Cash/Debt	$41M	$-106M
Current Ratio (TTM)	34.46x	2.33x
Quick Ratio (TTM)	34.24x	2.23x
Debt/Equity (TTM)	0.18x	6.07x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.64	2.81
52W Performance	-37.7%	43.3%
YTD Performance	-34.6%	78.8%
% from 52W High	-51.0%	-4.7%
% from 52W Low	8.9%	105.6%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.38x
FCF Yield (TTM)	-16.5%	-2.0%
Earnings Yield (TTM)	-17.0%	-11.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-72.0
EV/GP/RG	N/A	N/A
Ticker research	View MLYS research	View NVAX research